Investor Relations LatestPress Releases Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Dec 10, 2024 Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA Dec 09, 2024 Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer btn News IR View All RecentEvents Oct 10, 2024 10 Oct 2024 at 8:30 AM EDT Third-Quarter Fiscal 2024 Financial Results Conference Call Listen to Webcast Jul 10, 2024 10 Jul 2024 at 8:30 AM EDT Second-Quarter Fiscal 2024 Financial Results Conference Call Listen to Webcast May 09, 2024 09 May 2024 at 10:00 AM EDT Annual Meeting of Shareholders Listen to Webcast btn Events View All Financial InformationLatest Earnings Show all Q3 2024 Financial Statement 639.2 KB MD&A 892.4 KB btn QRs View More PresentationsInvestor Presentation Download PDF
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Dec 10, 2024 Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
Dec 09, 2024 Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
Oct 10, 2024 10 Oct 2024 at 8:30 AM EDT Third-Quarter Fiscal 2024 Financial Results Conference Call Listen to Webcast
Jul 10, 2024 10 Jul 2024 at 8:30 AM EDT Second-Quarter Fiscal 2024 Financial Results Conference Call Listen to Webcast